SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): April 26, 2019
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
incorporation or organization)
12780 El Camino Real,
San Diego, California
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (858) 617-7600
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On April 25, 2019, Express Scripts published its updated 2019 National Preferred Formulary exclusions list, announcing changes to its formulary list that will exclude INGREZZA® (valbenazine) as a drug for its National Preferred formulary for commercial patients, effective July 1, 2019. While Express Scripts National Preferred currently accounts for less than one percent of INGREZZA product revenue, we continue to engage with Express Scripts and value our relationship with them. Given that INGREZZA is the most preferred drug for tardive dyskinesia in the marketplace, we are committed to ensuring patients have access to INGREZZA and have worked diligently since the INGREZZAs launch to ensure its availability. Since launching the product, Neurocrine has worked closely with payors to ensure appropriate coverage policies for INGREZZA, and will continue to do so.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|NEUROCRINE BIOSCIENCES, INC.|
|Dated: April 26, 2019||By:||/s/ Darin M. Lippoldt|
|Darin M. Lippoldt|
|Chief Legal Officer|